Joint Infringement Litigation More Common in Personalized Medicine Cases, Lawyers Say

Speaking on “The Divide on Joint Infringement” at the November 3, 2011 BIO IP Counsels Committee Conference in New York, Finnegan partner Kara F. Stoll made the argument that litigation for joint infringement is becoming more and more common in patent cases concerning personalized medicine, especially those that involve the use of web content. Ms. Stoll, who represents the appellant in Akamai Technologies Inc. v. Limelight Networks Inc., discussed her case involving different actors performing different steps in method patent claims. For example, in the Akamai matter, the patent in question covers an improved method of delivering web page content in which the content provider, such as a website, delivers part of the page and the content delivery network, delivers the remainder of the content.